A Phase I Study of SU5416 [semaxanib] in Pediatric Patients With Recurrent or Progressive Poor Prognosis Brain Tumors.

Trial Profile

A Phase I Study of SU5416 [semaxanib] in Pediatric Patients With Recurrent or Progressive Poor Prognosis Brain Tumors.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2009

At a glance

  • Drugs Semaxanib (Primary)
  • Indications Brain cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 20 Oct 2009 Planned end date (Mar 2006) added as reported by ClinicalTrials.gov.
    • 20 Oct 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 21 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top